Oncolytic Virotherapy Europe Congress returns to London
Posted: 2 February 2017 | KCC Events | No comments yet
The Oncolytic Virotherapy Europe Congress is the only conference in Europe dedicated specifically to the Oncolytic Virotherapy and converting research into the next generation of clinically-relevant virotherapeutics.
This year it will be held in London, and attendees will gain access to the very latest clinical progress and exclusive case studies.
The conference is partnering up with some of the most innovative oncolytic virotherapy pioneers including Transgene, PsiOxus Therapeutic, Lokon, Virttu, Oxford Genetics, Targovax, VCN Biosciences and many more.
Investment and interest in oncolytic virotherapy has gathered significant momentum in the industry since T-VEC (Talimogene laherparepvec) was granted approval. Research has shown how effective and efficient it can be, however significant challenges remain.
Drug Target Review has just announced the launch of its NEW and EXCLUSIVE report examining the evolution of AI and informatics in drug discovery and development.
In this 63 page in-depth report, experts and researchers explore the key benefits of AI and informatics processes, reveal where the challenges lie for the implementation of AI and how they see the use of these technologies streamlining workflows in the future.
Also featured are exclusive interviews with leading scientists from AstraZeneca, Auransa, PolarisQB and Chalmers University of Technology.
For more information, visit www.oveccongress.com
Related topics
Therapeutics
Related organisations
KCC Events
